Gemcitabine and Capecitabine With or Without T-ChOS as Adjuvant Therapy for Patients With Resected Pancreatic Cancer
This is a single center, randomized, double-blind, placebo-controlled phase II trial that will compare the efficacy of T-ChOS in combination with gemcitabine to gemcitabine alone as adjuvant treatment for 6 months in patients with surgically resected pancreatic adenocarcinoma.
Pancreatic Cancer
DIETARY_SUPPLEMENT: T-ChOS|DRUG: Gemcitabine|DIETARY_SUPPLEMENT: Placebo|DRUG: Capecitabine
Disease-free survival (DFS), Time from the date of randomization to the date of disease recurrence or death, whichever is earlier., up to approximately 9 months
Overall Survival, Time from the date of randomization to the date of death, up to approximately 18 months|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0, Assesment by CTCAE v4.0, up to approximately 18 months|Quality of Life, Quality of Life Questionnaire C30 (QLQ-C30) Version 3.0, up to approximately 18 months
Determination of plasma YKL-40, Measurement using an enzyme linked-immunosorbent assay, up to approximately 9 months|Determination of plasma IL-6, Measurement using an enzyme linked-immunosorbent assay, up to approximately 9 months
This is a single center, randomized, double-blind, placebo-controlled phase II trial that will compare the efficacy of T-ChOS in combination with gemcitabine to gemcitabine alone as adjuvant treatment for 6 months in patients with surgically resected pancreatic adenocarcinoma.